![Jan Smeitink](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Cargos activos de Jan Smeitink
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Khondrion BV
![]() Khondrion BV Pharmaceuticals: MajorHealth Technology Khondrion BV is a Dutch clinical-stage biopharmaceutical company that focuses on discovering and developing therapies for mitochondrial diseases. The company is based in Nijmegen, Netherlands, and was founded in 2012 by Jan Smeitink, who has been the CEO since then. The company's lead drug candidate, sonlicromanol, is a first-in-class, oral small molecule that targets key underlying mechanisms of primary mitochondrial disease. The compound has been granted orphan drug designations for the treatment of various mitochondrial diseases. Khondrion collaborates with a clinical and academic network and patient organizations internationally to accelerate the discovery and development of its potential medicines. | Director Ejecutivo | 01/01/2012 | - |
Fundador | 01/01/2012 | - |
Historial de carrera de Jan Smeitink
Estadísticas
Internacional
Países Bajos | 2 |
Operativa
Chief Executive Officer | 1 |
Founder | 1 |
Sectorial
Health Technology | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas privadas | 1 |
---|---|
Khondrion BV
![]() Khondrion BV Pharmaceuticals: MajorHealth Technology Khondrion BV is a Dutch clinical-stage biopharmaceutical company that focuses on discovering and developing therapies for mitochondrial diseases. The company is based in Nijmegen, Netherlands, and was founded in 2012 by Jan Smeitink, who has been the CEO since then. The company's lead drug candidate, sonlicromanol, is a first-in-class, oral small molecule that targets key underlying mechanisms of primary mitochondrial disease. The compound has been granted orphan drug designations for the treatment of various mitochondrial diseases. Khondrion collaborates with a clinical and academic network and patient organizations internationally to accelerate the discovery and development of its potential medicines. | Health Technology |
- Bolsa de valores
- Insiders
- Jan Smeitink
- Experiencia